Pre Diabetes? How To Stop It From Progressing. Explained By Endocrinologist Dr Alice Cheng

Pre-Diabetes: The Window of Opportunity Most People Miss

Dr. Alice Cheng, an endocrinologist, joins the Talking With Docs podcast to explain something that affects roughly 96 million Americans: pre-diabetes. That's about 1 in 3 adults. And the majority of them don't know they have it. This video is a wake-up call, but it's also a reassuring one, because pre-diabetes is the stage where intervention works best and the condition can often be fully reversed.

Pre-diabetes is defined by blood sugar levels that are higher than normal but not yet high enough for a diabetes diagnosis. There are three ways to identify it: fasting glucose between 100-125 mg/dL, A1c between 5.7-6.4%, or a 2-hour glucose tolerance test result between 140-199 mg/dL. Dr. Cheng makes the point that these aren't just numbers. They represent a metabolic state where insulin resistance has taken hold, the pancreas is working overtime to compensate, and the system is slowly losing the battle.

The progression from pre-diabetes to type 2 diabetes isn't inevitable. That's the central message of this conversation. About 5-10% of people with pre-diabetes convert to diabetes each year if nothing changes. But lifestyle interventions can cut that conversion rate by more than half. The Diabetes Prevention Program (DPP), one of the largest prevention trials ever conducted, showed that moderate weight loss (about 7% of body weight) and 150 minutes of weekly exercise reduced diabetes progression by 58%. That's more effective than metformin was in the same trial.

Where GLP-1 Drugs Fit in Pre-Diabetes

Dr. Cheng discusses the emerging role of GLP-1 medications in pre-diabetes prevention, and this is where the conversation gets particularly relevant for the GLP-1-curious audience. While GLP-1 drugs are not FDA-approved for pre-diabetes specifically, the STEP 1 and SELECT trials included patients across the metabolic spectrum, and the weight loss and metabolic improvements seen in these trials would logically benefit pre-diabetic patients.

Some endocrinologists are already prescribing GLP-1 drugs off-label for patients with pre-diabetes who haven't responded adequately to lifestyle changes, particularly those with a BMI over 30 or those with additional metabolic risk factors like fatty liver disease or cardiovascular risk. The argument is straightforward: if a drug can produce the 7-10% weight loss that the DPP showed prevents diabetes, and if it also directly improves insulin sensitivity and beta-cell function, why wait until the patient has crossed the arbitrary diagnostic threshold into diabetes?

The counter-argument, which Dr. Cheng acknowledges, is about cost and sustainability. GLP-1 drugs are expensive, and using them for prevention means potentially decades of treatment. There's also the question of whether the benefits persist if the drug is stopped. Current data suggests that much of the metabolic improvement reverses when GLP-1 drugs are discontinued, which makes a strong case for lifestyle changes as the foundation even if medication is added.

What the Video Gets Right

The emphasis on pre-diabetes as a reversible condition is the most important message. Too many people learn they're pre-diabetic and assume diabetes is inevitable. Dr. Cheng counters that fatalism with data, showing that intervention at this stage is the most effective time to act. The DPP trial data is presented clearly and convincingly.

The balanced discussion of medication versus lifestyle changes is also well-handled. Dr. Cheng doesn't dismiss either approach. She presents them as complementary tools, with lifestyle changes as the foundation and medication as an accelerator when needed.

What's Missing

The video could go deeper into the specific lifestyle interventions that work best. "Lose 7% of your body weight and exercise 150 minutes per week" is the DPP headline, but the details matter. What kind of exercise? What kind of diet? The DPP used a moderate-intensity walking program and a calorie-restricted diet. But more recent research suggests that resistance training may be particularly effective for improving insulin sensitivity, and dietary approaches focused on reducing refined carbohydrates and increasing fiber may be more effective than simple calorie restriction.

There's also no discussion of screening frequency. If you've been told your fasting glucose is 105 (technically pre-diabetic), how often should you recheck? Annually? Every 6 months? The answer depends on your risk profile, and having this guidance would help patients stay engaged in monitoring.

Questions for Your Doctor

If you've been told you're pre-diabetic, or if you haven't been screened recently:

Ask for a fasting insulin level in addition to fasting glucose. Insulin levels rise before glucose levels do, so a high fasting insulin with normal glucose means you're in an even earlier stage of metabolic dysfunction that's still very treatable. Ask about your A1c trend. A single A1c of 5.8% is less concerning if your previous tests were 5.7% and 5.7%. But if you've gone from 5.3% to 5.8% in two years, the trajectory matters more than the absolute number.

Ask about a referral to a diabetes prevention program. Many insurance plans cover DPP-modeled programs that provide structured coaching on diet and exercise. Ask whether medication (metformin or a GLP-1 drug) makes sense for your specific risk profile. If you've tried lifestyle changes and your numbers are still drifting upward, medication isn't defeat. It's a rational escalation. Ask about other metabolic risk factors. Pre-diabetes rarely exists in isolation. Checking lipids, liver function, blood pressure, and waist circumference gives a fuller picture of your metabolic health.

Understanding Insulin Resistance Before It Becomes Diabetes

One of the most empowering concepts in this video is the idea that insulin resistance, the precursor to pre-diabetes and diabetes, is detectable and treatable years before blood sugar numbers become abnormal. In the typical progression from normal metabolism to diabetes, the earliest detectable change is hyperinsulinemia, the pancreas producing more insulin than normal to maintain normal blood sugar levels. This is the metabolic equivalent of shouting louder and louder to be heard in a noisy room. The message is getting through (blood sugar stays normal), but the effort required to deliver it is increasing unsustainably.

A fasting insulin level is the simplest way to detect this early stage of metabolic dysfunction. A fasting insulin above 10 mIU/L is often considered a marker of early insulin resistance, even when fasting glucose and A1c are normal. By the time fasting glucose rises above 100 (the lower threshold for pre-diabetes), the insulin resistance has typically been present for 5-10 years. This detection gap represents a massive missed opportunity for intervention, because the earlier you address insulin resistance, the easier it is to reverse.

The Lifestyle Changes That Actually Move the Needle

The Diabetes Prevention Program (DPP) demonstrated that lifestyle changes are more effective than metformin for preventing diabetes progression, but the specifics of those lifestyle changes matter. The DPP intervention targeted 7% body weight loss and 150 minutes of moderate-intensity physical activity per week. Participants received intensive coaching, including 16 individual sessions in the first 24 weeks covering diet, exercise, and behavioral strategies. The results were dramatic: 58% reduction in diabetes progression, sustained for up to 15 years in follow-up studies.

But replicating DPP results in the real world has been challenging because the intensive coaching component is expensive and hard to scale. National DPP-modeled programs are now available through many insurance plans, community organizations, and even employers, but awareness of these programs is low. If you've been told you're pre-diabetic, asking your insurance company about covered DPP programs is a concrete first step. Some programs are delivered in person, others online, and they typically run for a year with weekly sessions in the first few months transitioning to monthly sessions later. The success rates are lower than in the original trial but still meaningful, and they provide the structured support that makes behavior change stick.

When Medication Makes Sense for Pre-Diabetes

The decision to add medication for pre-diabetes is nuanced and should be individualized. The ADA recommends metformin for pre-diabetic patients who have a BMI above 35, are under 60 years old, or have a history of gestational diabetes, because these groups have the highest conversion rates to diabetes. GLP-1 drugs are not officially recommended for pre-diabetes, but the biological rationale is strong. These medications improve insulin sensitivity, promote weight loss, reduce inflammation, and may preserve pancreatic beta-cell function, all of which are directly relevant to preventing diabetes progression.

The counterargument, which Dr. Cheng raises fairly, is about cost and sustainability. Using a $1,000/month medication to prevent a condition that can potentially be prevented with diet and exercise raises questions about resource allocation. A pragmatic approach might involve tiered intervention: lifestyle changes first, adding metformin if targets aren't met after 6 months, and considering a GLP-1 drug if lifestyle changes plus metformin aren't sufficient. This stepwise approach uses the most cost-effective interventions first while keeping more intensive options available for patients who need them. The important thing is that something is done. A pre-diabetes diagnosis that leads to no action, which happens far too often in clinical practice, is a missed opportunity that often results in predictable progression to diabetes.

Who Should Watch This

Anyone over 35 with a family history of diabetes, a BMI over 25, or any history of gestational diabetes should watch this. If you've been told you're pre-diabetic and were sent home without a clear action plan, this video gives you the framework to create one. It's also useful for healthcare providers who want a patient-friendly resource to share after delivering a pre-diabetes diagnosis. The conversational podcast format makes it easy to listen to, and at 211K views, it's clearly resonating with an audience that needed to hear this message.